Sanofi Exercises Option on Recursion's First Development Candidate, Triggering a $10 Million Milestone Payment
Article excerpt
Recursion Pharmaceuticals announced (RXRX) that, on October 15, 2026, Sanofi exercised its option on the first development candidate from the two companies' multi-program research collaboration, triggering a $10 million US milestone payment to Recursion and advancing a potentially first-in-class oral small molecule in immunology into Sanofi's development pipeline. According to the company, the exercise of the option brings total upfront and milestone payments received from Sanofi under the collaboration to $144 million. Recursion remains eligible for over $300 million in additional milestone payments for the program, as well as mid-single-digit to low-double-digit royalties on net product sales if the candidate is successfully commercialized. The $10 million milestone payment will be recorded as revenue in the third quarter of 2026. According to the company, the exercise of the option terminates Recursion's operational obligations related to the candidate, and all future payments will constitute profit for Recursion. The candidate is an orally administered small molecule designed to exhibit a differentiated profile against a challenging dual target involved in inflammatory diseases. Recursion stated that optimization targeting this target pair required navigating complex and competing chemical constraints to achieve the desired balance of drug-like properties. Its teams also...
Keep reading with a free account
The rest of this article, and every signal for Sanofi, is in your free account.
Extracted from this sentence
According to Recursion, the candidate has been added to Sanofi's development pipeline and is expected to enter Phase 1 clinical trials in 2027.
